Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Koji Haratani"'
Autor:
Kimio Yonesaka, Junko Tanizaki, Osamu Maenishi, Koji Haratani, Hisato Kawakami, Kaoru Tanaka, Hidetoshi Hayashi, Kazuko Sakai, Yasutaka Chiba, Asuka Tsuya, Hiroki Goto, Eri Otsuka, Hiroaki Okida, Maki Kobayashi, Ryoto Yoshimoto, Masanori Funabashi, Yuuri Hashimoto, Kenji Hirotani, Takashi Kagari, Kazuto Nishio, Kazuhiko Nakagawa
Publikováno v:
Clinical Cancer Research. 28:390-403
Purpose: EGFR-tyrosine kinase inhibitor (TKI) is a standard first-line therapy for activated EGFR-mutated non–small cell lung cancer (NSCLC). Treatment options for patients with acquired EGFR-TKI resistance are limited. HER3 mediates EGFR-TKI resis
Autor:
Hidetoshi Hayashi, Shunichi Sugawara, Yasushi Fukuda, Daichi Fujimoto, Satoru Miura, Keiichi Ota, Yuichi Ozawa, Satoshi Hara, Junko Tanizaki, Koichi Azuma, Shota Omori, Motoko Tachihara, Kazumi Nishino, Akihiro Bessho, Yasutaka Chiba, Koji Haratani, Kazuko Sakai, Kazuto Nishio, Nobuyuki Yamamoto, Kazuhiko Nakagawa
Publikováno v:
Clinical Cancer Research. 28:893-902
Purpose: Although the efficacy of programmed cell death–1 (PD-1) blockade is generally poor for non–small cell lung cancer (NSCLC) with activating mutations of the epidermal growth factor receptor (EGFR) gene, EGFR tyrosine kinase inhibitors (TKI
Autor:
Toshiyuki Takehara, Kimio Yonesaka, Hitomi Sakai, Koji Haratani, Hidetoshi Hayashi, Kazuko Sakai, Hisato Kawakami, Kazuhiko Nakagawa, Takeshi Teramura, Shinichiro Suzuki, Kazuto Nishio, Ryoji Kato, Junko Tanizaki
Publikováno v:
Clinical Cancer Research. 27:5697-5707
Purpose: Treatment with KRASG12C inhibitors such as sotorasib can produce substantial regression of tumors in some patients with non–small cell lung cancer (NSCLC). These patients require alternative treatment after acquiring resistance to the inhi
Autor:
Shuta Tomida, Takashi Ogura, Tadashi Ishida, Shigeki Shimizu, Hidetoshi Hayashi, Koji Haratani, Masayuki Takeda, Junko Tanizaki, Ryoji Kato, Kohsuke Isomoto, Yasutaka Chiba, Akihiko Ito, Kazuhiko Nakagawa, Takashi Niwa, Kaoru Tanaka, Yasushi Fukuda, Toshihide Yokoyama
Publikováno v:
Clinical Cancer Research. 26:2037-2046
Purpose: The impact of EGFR tyrosine kinase inhibitors (TKI) on the tumor immune microenvironment (TME) in non–small cell lung cancer (NSCLC) is unclear. Experimental Design: We retrospectively identified 138 patients with EGFR-mutated NSCLC who un
Autor:
Shinichiro Suzuki, Kimio Yonesaka, Takeshi Teramura, Toshiyuki Takehara, Ryoji Kato, Hitomi Sakai, Koji Haratani, Junko Tanizaki, Hisato Kawakami, Hidetoshi Hayashi, Kazuko Sakai, Kazuto Nishio, Kazuhiko Nakagawa
Publikováno v:
Clinical Cancer Research. 28:428-428
Autor:
Koji Haratani, Yasutaka Chiba, Shiki Takamura, Takafumi Okabe, Kenji Hirotani, Hiroyasu Kaneda, Michiko Yamato, Kaoru Tanaka, Shigeki Kato, Kazuhiko Nakagawa, Kazuto Nishio, Hidetoshi Hayashi, Yoshikazu Hasegawa, Masayuki Takeda, Kazuko Sakai, Kimio Yonesaka, Masaaki Miyazawa, Osamu Maenishi, Ryoji Kato, Naoki Takegawa, Takayuki Takahama, Hitomi Sakai, Keita Kudo
Publikováno v:
Clinical Cancer Research. 24:2653-2664
Purpose: Anti-programmed-death-1 (PD-1) immunotherapy improves survival in non–small cell lung cancer (NSCLC), but some cases are refractory to treatment, thereby requiring alternative strategies. B7-H3, an immune-checkpoint molecule, is expressed